Tianjin TEDA Biomedical Clarifies 4,000,000-Share Award Requires No Shareholder ApprovalPUBT·Oct 26, 2026 at 08:36 AM081890.00%
Tianjin TEDA Biomedical Grants 4,000,000 Shares to Subsidiary Director Li WanchenPUBT·Oct 21, 2026 at 10:15 AM081890.00%
Tianjin TEDA Biomedical Engineering announces extraordinary general meetingPUBT·Sep 7, 2026 at 09:52 AM081890.00%
Tianjin TEDA Biomedical Engineering swings to FY26 H1 profit of RMB 10.21 million; revenue rises 30.75% to RMB 296.03 millionPUBT·Aug 31, 2026 at 01:51 PM081890.00%
Tianjin TEDA Biomedical Engineering schedules board meeting on half-year results, interim dividend decisionPUBT·Aug 14, 2026 at 08:36 AM081890.00%
JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIOAASTOCKS News·May 12, 2026 at 04:08 AM02509-0.07%603259-1.34%
Morgan Stanley's investment ratings and target prices for Chinese biopharmaceutical stocks (Table)AASTOCKS·Mar 3, 2026 at 02:30 AM081890.00%02561-7.54%